Stan Smith, Director at MAIA Biotechnology, Inc. (MAIA), bought 221 shares at $4.48 ($988) on 2023-03-01, disclosed to the SEC on 2023-03-03.
Scheduled purchase ($988) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.48 | 198 | $887 | 89.7% |
| 2 | $4.41 | 23 | $101 | 10.3% |
| Total | $4.47 avg | 221 | $988 | 100% |
| Filing → |
| MAIA | BUY | 2025-12-23 | $140K | — | Filing → |
| MAIA | BUY | 2025-12-09 | $11K | — | Filing → |
| MAIA | BUY | 2025-12-01 | $16K | — | Filing → |